Autolus Therapeutics plc

4.34 USD
-0.02 (-0.46%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Autolus Therapeutics plc stock is up 26.53% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
28 Nov 16:41 15 Dec, 2023 5.00 PUT 682 3
28 Nov 16:45 15 Dec, 2023 5.00 PUT 191 3

About Autolus Therapeutics plc

Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.